Saving money is wise, but investing is profitable
In accordance with the legislation of the Czech Republic, the Company provides services only to qualified investors!

Achilles Therapeutics (ACHL) FINANCIAL RESULTS FOR SECOND QUARTER 2022.

09.08.2022

Non-GAAP net loss per share for the second quarter of 2022 was -0.44 dollars.  
 
Cash and cash equivalents amounted to $201.6 million in the second quarter.